Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinet... (

Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile

Date:11/19/2008

       - Marine omega-3 phospholipids in NKO(R) outperform established
           nutraceutical and pharmaceutical omega-3 formulations -

       - Study results used to direct Acasti Pharma's prescription drug
                                  program -

LAVAL, QC, Nov. 19 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) is pleased to announce positive results from a human clinical trial conducted in Germany in order to study the pharmacokinetic profile of Neptune Krill Oil NKO(R). The objective of the trial was to evaluate the bioavailability and steady state assessment of NKO(R) in a low physiological daily dose and compare it to well-established nutraceutical and pharmaceutical omega-3 formulations by measuring the levels of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma and erythrocytes.

The clinical study was conducted under controlled, randomized, double-blind and mono-centric conditions, and comprised of a parallel design with four groups of twelve healthy male volunteers each. One of the four groups received NKO(R) (where EPA and DHA are primarily bound to phospholipids), and the three other groups received either a formulated krill oil-like blend, or concentrated DHA/ EPA ethyl esters (where EPA and DHA are primarily ester bound) or a pharmaceutical grade fish oil (where EPA and DHA are primarily bound to triglycerides).

The trial was designed to compare the acute and long-term bioavailability of the omega-3 fatty acids EPA and DHA of each of the formulations standardized to a low physiological daily dose of 500 mg NKO(R). Concentrations of the omega- 3 fatty acids EPA and DHA were analyzed in plasma and erythrocyte membranes at defined time points of 1 day, 7 days, 28 days, 56 days and 112 days, enabling the measure of accumulation, steady state and bioavailability during the normal lifespan of th
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources

Post Your Comments:

(Date:5/16/2012)... 2012 Reportlinker.com announces that ... available in its catalogue: , ... http://www.reportlinker.com/p090668/Global-Biotechnology-Instrumentation-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_ This ... Biotechnology Instrumentation in US$ Million by ... Protein/Peptide Synthesizers, DNA Sequencers, Protein/Peptide Sequencers, ...

(Date:5/16/2012)... WOONSOCKET, R.I., May 16, 2012 MultiCell ... MCET ) is pleased to announce representatives ... findings for MCT-465 and MCT-485 at CIMT ... dedicated to cancer immunotherapy research and development. ... 23-25 in Mainz, Germany. The title of ...

(Date:5/15/2012)... Vermillion, Inc. (NASDAQ: VRML ), ... results for the first quarter ended March 31, 2012. ... In Q1, the volume of OVA1®, the company,s flagship ... ovarian masses, was generally in line with the forecast ... increase of 28% to 3,952 from the same year-ago ...

(Date:5/15/2012)... -- Cardium Therapeutics (NYSE Amex: CXM ... first quarter ended March 31, 2012, and other ... In addition to the announcement ... its goals for 2012, which were outlined in ... advance commercialization of its new Excellagen® advanced, physician-use ...

[0] Global Biotechnology Instrumentation Industry [0] MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models [0] Vermillion Reports First Quarter 2012 Results [0] Cardium Presents First Quarter 2012 Financial Results and Recent Developments

... Neurological Function Now Available in the US, ... a new product called NeuroAid10(TM) in the US ... from,NeuroAid(TM) and is a combination of ten all-natural ... together the best of Asian,and Western medicine., ...

... Calif., March 6 Senetek PLC (OTC,Bulletin Board: ... development,of technologies that target the science of healthy ... two Veteran Sales and Marketing Executives,and the appointment ... Campagnoli joined the Company in December and has ...

... Inc., a,biodefense company specializing in the development and ... announced,today that it has completed the initial pharmacokinetic ... nerve agent prophylaxis., The PK studies were ... final,pegylated version of rBChE for the first time. ...

Other Biology Technology:Moleac Launches NeuroAid10(TM) in the United States 2 Moleac Launches NeuroAid10(TM) in the United States 3 Senetek PLC Announces Appointments of Key Personnel 2 Senetek PLC Announces Appointments of Key Personnel 3 PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 2 PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 3 PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 4

Moleac Launches NeuroAid10(TM) in the United States Senetek PLC Announces Appointments of Key Personnel PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008

(Date:5/21/2012)... US scientists has found there has been a massive ... off the coast of Antarctica.,Comparing detailed measurements taken during ... voyage to historical data dating back to 1970, scientists ... per cent reduction in the volume of Antarctic Bottom ... currents. , In an intensive and arduous 25-day observing ...

(Date:5/20/2012)... ARLINGTON, VA (May 14, 2012) - ... groundbreaking research being unveiled at the American Association ... The conference takes place Monday, May 21 - ... Hotel and Marina. Other topics to be discussed ... and tech transfer strategies, applications of multi-scale systems ...

(Date:5/20/2012)... uses a trial-and-error process to mimic the song of its ... times a day, making subtle changes in the pitch of ... process begins around the age of 40 days and is ... and ready to use his song to woo females. , ... process large quantities of information about its performance and use ...

Breaking Biology News(10 mins):Latest Southern Ocean research shows continuing deep ocean change 2 Latest Southern Ocean research shows continuing deep ocean change 3 AAPS National Biotechnology Conference to highlight innovative vaccines 2 Songbirds' learning hub in brain offers insight into motor control 2 Songbirds' learning hub in brain offers insight into motor control 3 Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference 11873 1 Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference 11873 2 iGPS Announces iGPS bios u2122 a New Pallet Rental Service Designed Exclusively for the Pharmaceutical and Life Sciences Industries 11869 1 iGPS Announces iGPS bios u2122 a New Pallet Rental Service Designed Exclusively for the Pharmaceutical and Life Sciences Industries 11869 2 iGPS Announces iGPS bios u2122 a New Pallet Rental Service Designed Exclusively for the Pharmaceutical and Life Sciences Industries 11869 3 Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 15966 1 Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 15966 2 Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 15966 3

[0] Latest Southern Ocean research shows continuing deep ocean change [0] AAPS National Biotechnology Conference to highlight innovative vaccines [0] Songbirds' learning hub in brain offers insight into motor control

... research in an animal model suggests that a diet ... variety of processed foods including meats, cheeses, beverages, and ... and may even contribute to the development of those ... study also suggests that dietary regulation of inorganic phosphates ...

... 12 WCC Smart Search & Match,the leading ... that Rudie Lion has joined the company as ... brings more than 15 years of product and ... market introduction efforts,for many high-tech products and solutions ...

... can halt the might of a tsunami are false and ... There are many reasons for preserving the world,s dwindling stocks ... of them, they say. , On the eve ... which claimed nearly a quarter of a million lives around ...

Other Biology News:Common food additive found to increase risk and speed spread of lung cancer 2 Common food additive found to increase risk and speed spread of lung cancer 3 Trees won't stop tsunamis, scientists warn 2 Trees won't stop tsunamis, scientists warn 3

Common food additive found to increase risk and speed spread of lung cancer WCC Smart Search and Match Names Rudie Lion - Product Marketing Manager Trees won't stop tsunamis, scientists warn

... The Tetrad 2 thermal cycler is a ... original Tetrad chassis, and it accepts the ... It delivers the same precision in thermal ... original Tetrad thermal cyclers, allowing easy transport ...

... The new Pierce ready-to-use 2-D gel marker ... analyst. This 2-D gel marker mix contains a ... offer important features of value to those who ... estimate pI and molecular weight values of proteins ...

... Tetrad thermal cycler expands the envelope ... DNA Engine cycler. It ... a footprint only twice the size, ... that run massive quantities of reactions, ...

The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....

Biology Products:

DNA Engine Tetrad 2 Peltier Thermal Cycler, w/4 x 384-well blocks & motorized lid from Bio-Rad 2-D MARKER from Pierce Biotechnology, Inc.DNA Engine Tetrad 2 Peltier Thermal Cycler, w/4 x 384-well blocks from Bio-Rad Sealed Ice Blocks, for Criterion blotter, 2 from Bio-Rad

Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinet...( - Marine omega-3 phospholipids in...)